Furthermore, the mechanistic studies of PEA’s action showed that these positive effects were obtained through a PPAR α-dependent pathway, which makes palmitoylethanolamide promising as a novel treatment for HPA axis dysfunction and anxiety, related to obesity. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.